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Background: Metabolic syndrome is an obesity dependent disorder with a worldwide high prevalence. Regarding
the high prevalence of Metabolic syndrome in Iran we analyzed the influence of -1131T>C (rs662799) and c.56C>G
(S19W, rs3135506) polymorphisms of the novel apolipoprotein gene, ApoA5, on some Metabolic Syndrome
indicators in population from north of Iran.
Methods: 199 volunteers from Babol city-Iran were divided in two groups of low (N = 99, TG ≤ 103 mg/dl) and high
(N = 100, TG ≥ 150 mg/dl) serum levels of Triglycerides (TG). We amplified the gene fragments containing -1131T>C
and c.56C>G polymorphisms by PCR method and revealed the polymorphisms by RFLP analysis.
Results: We found a significant association (p = 0.016, Independent t-test) between high levels of TG and -1131T>C
polymorphism but not between this polymorphism and serum HDL-C concentrations. Carriers of the C allele had a
1.97 times higher odds ratio to be in the high-TG group than those of the TT genotype (95%, CI = 1.05-3.68). We
observed no association between -1131T>C polymorphism with either Waist-to-Hip Ratio (WHR) or Body-Mass-Index
(BMI). In the case of c.56C>G polymorphism, although it showed a significant relationship with WHR (p = 0/040,
Independent t-test), but failed to correlate with either levels of TG (p = 0.594) or HDL-C (p = 0.640) in serum.
Conclusion: Our study confirms that ApoA5 gene polymorphisms, -1131T>C and c.56C>G are associated with the two
criteria of Metabolic Syndrome, TG and WHR, respectively.
Keywords: -1131T>C (rs662799), c.56C>G (S19W, rs3135506), Triglyceride, WHRBackground
Metabolic syndrome (MetS) is a combination of clin-
ical and paraclinical signs characterized by abdominal
obesity, dyslipidemia (high triglyceride (TG), low
HDL-cholesterol (HDL-C)), hypertension and hyper-
glycemia (3 out of 5). Several definitions have been
presented to diagnose MetS, with the most earliest
being the WHO definition, which declares high TG
and waist-to-hip ratio (WHR) as the basic criteria [1].
Recent studies presented hypertriglyceridemia as a
hallmark of MetS [2]. Also, Hypertriglyceridemia can* Correspondence: Shojaeish@sums.ac.ir
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unless otherwise stated.subsequently result in serum HDL-C reduction, an-
other hallmark of MetS [2,3].
MetS has been known as a risk factor for cardiovascu-
lar disease (CVD) and diabetes mellitus [4] and has an
increasing rate of prevalence globally [5,6]. The preva-
lence of MetS based on National Cholesterol Education
Program Adult Treatment Panel III (NCEP ATP III) in
Iran varies from 21% in southeast [7] to 23.7% in the
west [8] and 29.9% in the center [9] with higher rate in
women than men. It is worth mentioning that the preva-
lence of MetS is 31% among women in the north [10].
The exact pathological mechanism of MetS has not
yet been clarified but it has been established that both
environmental and genetic factors are involve [11-13].
ApolipoproteinA5 (ApoA5) gene which is located onal Ltd. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
iginal work is properly credited. The Creative Commons Public Domain
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A5 gene cluster has been recently discovered [14]. Des-
pite its low plasma concentration, ApoA5 has been
shown to have great effect on the plasma TG concentra-
tion [15,16]. These effects are partially attributed to the
role of ApoA5 on TG metabolism (Reviewed in [17]) as
well as to its influence on food intake [18].
Molecular mechanism of ApoA5 effect on TG metab-
olism is not completely understood. ApoA5 is suggested
to impede the second step of VLDL gathering [19]. In
vivo studies on human ApoA5 transgenic mice demon-
strated that ApoA5 could interact with lipoprotein lipase
and significantly increase its activity [20]. These results
suggest that ApoA5 might induce a decrease in VLDL
associated TG levels by both decreasing hepatic VLDL
synthesis and increasing VLDL clearance. Besides, a re-
cent study showed that ApoA5 may be absorbed by hu-
man adipocytes and may play a role in TG storage
regulation [21].
Two polymorphisms of ApoA5, -1131T>C (rs662799)
and c.56C>G (rs3135506) have been shown to be associ-
ated with TG level and dyslipidemia in different ethnics
[22-25]. ApoA5 -1131T>C polymorphism is located in
the promoter of ApoA5 gene; therefore, it is expected to
affect gene transcription and consequently serum ApoA5
levels. Relationship between ApoA5 level and TG has
been reported in some research [26].
c.56C>G polymorphism of APOA5 gene has been
identified as a functional variant which tryptophan is
substituted with serine in signal peptide. This poly-
morphism results in decrease in ApoA5 secretion and 3
fold decline in plasma protein level with subsequent in-
crease in plasma TG [27].
With the aim of addressing the role of APOA5 poly-
morphisms in the high prevalence of MetS in the north
of Iran, we investigated the association of the two com-
mon polymorphisms of ApoA5 gene, -1131T>C and
c.56C>G, with the MetS criteria.
Subjects, material and methods
Ethical consideration
This cross-sectional study was performed from August
2008 to August 2009 in Babol, Iran. This study was done
in agreement with the Helsinki Declaration, following
approval by the ethical committee of the Medical school.
Written informed permission was obtained from all sub-
jects after ensuring them about safety of the procedure
and security of their information.Table 1 Sequences of primers used for each polymorphism
Polymorphism Forward primer
-1131T>C (rs662799) [34] GATTGATTCAAGATGC
c.56C>G (rs3135506) [23] CCACCCTGGGGGAGGAGASubjects
The study subjects were 199 men and woman with the
age of 30 to 73 years old. Volunteers had referred to Pars
laboratory in Babol-Iran from 2008-08-01 to 2009-08-17.
We obtained written, informed consent from the subjects.
Their personal data including age, living place, cigarette
and alcohol consumption, past medical history and drugs
consumption were collected through an interview. Those
who had diabetes, any thyroid disorders or being treated
for these disorders or who had an abnormal FBS or TSH
serum levels were excluded. Everyone with serum choles-
terol more than 300 mg/dl or treating with any drugs
that influence on lipid metabolism was omitted. Besides,
people with alcohol consumption or severe weight loss
during the previous two weeks were excluded too. An-
thropometric characteristics of the included individuals
such as: height, weight, hip and waist circumferences were
measured by a trained person, and then BMI and WHR
were calculated. The subjects based on serum TG level
were divided into two groups: low TG (TG ≤ 103 mg/dl)
including 49 men and 50 women and high TG (TG ≥
150 mg/dl) including 50 men and 50 women.Biochemical and DNA Analyses
10 ml of blood sample was taken from each individual
after overnight fasting, 5 ml for biochemical and 5 ml
for DNA extraction. Serum was separated immediately
after clotting and serum FBS, TG, total cholesterol, HDL-
C and LDL-cholesterol (LDL-C) levels were measured by
BS-300 MINDRAY (Shenzhen Mindray Bio-medical
Electronics Co., China) by DIASIS kits (Germany). Serum
TSH was measured by (AWARENESE, Stat Fax-200
model), using a commercially available ELISA DIAPLUS,
INC (Q1) kits (America). For quality control purpose
TruCal U Lot: 10929 and TruCal HDL/LDL, Lot: 10502
were used to calibrate the biochemical tests and TruLab
N, P Lot: 11382 and TruLab Lipid, Lot: 10501 were ap-
plied to check the accuracy of biochemical tests. To con-
trol the quality of TSH tests Dia Plus EIA, RIA, CLIA
Control Serum, Lot: MC1A5 was used.
Genomic DNA was extracted by the salting out method
from the peripheral blood. Genes of interest were ampli-
fied by 200 mM dNTP, 2U SmarTaq (Cinagen, Iran),
1× smarTaq buffer, 200 nM each primer 1.5 mM MgCl2
and 1 ul of DNA were mixed and the volume was adjusted
to 25 ul with water. PCR was performed by PRIMUS
(MWG-Biotech) thermal cycler. -1131T>C polymorphism(5′ > 3′) Reverse primer (5′ > 3′)
ATTTAGGAC CCCCAGGAACTGGAGCGAAATT
GCCCAAGCCCTG AGAGCTAGCACCGCTCCTT
Figure 1 Maps of the human APOA5 gene with polymorphism positions indicated. (A) Map of the human APOA5 gene. Exons 1-4 are
numbered and represented by solid boxes. (B) Position of the single nucleotide polymorphism within the core promoter of the APOA5 gene,
a T/C polymorphism at position -1131 and a C/G polymorphism at position 56.
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94°C for 15 s, 55°C for 30s, and 72°C for 30s and a final
extension at 72°C for 3 min to produce 187 bp fragments.
Products were digested with MseI (Tru1I) and resolved on
3% agarose gels post-stained with ethidium bromide and
imaged with SYNGENE transilluminator and INGENIUS
(SYNGENE BIO IMAGING) Gel Duct system. The re-
sulted segments in the presence of common allele T were
167 and 20 bp versus non digested 187 bp segment in the
presence of rare allele C.
For c.56C>G polymorphism fragment of interest was
amplified at 95°C for 10 min followed by 35 cycles of
95°C for 35 s, 58°C for 25 s and 72°C for 30s and a final
extension at 72°C for 2 min to produce 292 bp fragment.
PCR products were digested with Sau96I (Cfr13I) en-
zyme. After digestion we had 210 and 82 bp segments in
the presence of common allele C and 150, 82 and 60 bp
segments in the presence of rare allele G. Genotypes
were determined two times using blind reader method.
Sequences of used primer for each polymorphism have
been demonstrated in Table 1.Table 2 Allele frequency and genotype percent of
APOA5 -1131T>C (rs662799) in association with TGStatistical analyses
Statistical analyses were done using SPSS 10 and Micro-
soft excel. Allele frequencies in low and high TG groups
were accessed by χ2 test. Associations between geno-
types, lipids, and anthropometric parameters were evalu-
ated using independent t-test and One-way ANOVA.
Lipid levels were expressed in mg/dl and all values were
reported as means ± SD. P < 0.05 (two-tailed) was con-
sidered significant. Odds ratio was analyzed through lo-
gistic regression.Genotype TG
High1 Low2
TT 64 (64%) 77 (77.8%)
TC 31 (31%) 22 (22.2%)
CC 5 (5%) 0 (0%)
Total 100 99
1: High TG (≥150 mg/dl), 2: Low TG (≤ 103 mg/dl).Results
The groups were included 99 low TG (50 male age:
43.30 ± 12.15 and 49 female age: 46.53 ± 10.90 years) and
100 high TG (50 male age; 45.78 ± 11.20 and 50 female
48.40 ± 9.25 years) volunteers. The human APOA5 gene
map with polymorphism positions indicated in Figure 1.-1131T>C polymorphism
Allele frequencies of this polymorphism were in
Hardy–Weinberg equilibrium in both groups of high
and low TG. Genotypes in the high (TG ≥150 mg/dl) and
low (TG ≤103 mg/dl) TG groups have been shown in
Table 2. Both CC and TC genotypes were significantly as-
sociated with the high TG group (P = 0.02, χ2 test). The
frequencies of the rare allele C in the high and low TG
groups were 0.21 and 0.11 respectively. We found a higher
number of CC homozygotes in the highTG group as com-
pared with the low TG group. Likewise, the number of TC
heterozygotes in the high TG group was higher than those
in the low TG group.
We also considered CC and TC genotypes in one
group (allele C carriers) and used independent t-test to
compare the biochemical and anthropometric parame-
ters of subjects in this group with those of the volun-
teers with the TT genotype. Thus, a significant mean
difference was observed only between the levels of TG
in the two above mentioned groups (Table 3).
When the subjects were classified according to sex,
differences between the TG levels of men with the TT
genotype and those with CC and TC genotypes
remained statistically significant (Table 4). This differ-
ence did not achieve significance with respect to women.
Results of logistic regression analysis also showed that
the allele C carriers were associated with a high TG with
an odds ratio of 1.97 (95%, CI = 1.05-3.68) when com-
pared with subjects with TT genotype (Table 5). When
Table 3 Mean ± SD and P-value significance for phenotype
analysis of -1131T>C (rs662799) polymorphism
Parameter Genotype P-value£
TT CC and TC
TG (mg/dl) 153.46 ± 87.81 196.69 ± 154.36 0.016
Cholesterol (mg/dl) 196.48 ± 39.98 200.12 ± 41.67 0.565
LDL-C (mg/dl) 119.46 ± 31.73 116.48 ± 28.31 0.537
HDL-C (mg/dl) 47.19 ± 13.19 44.74 ± 14.20 0.247
BMI (kg/m2) 28.50 ± 4.68 29.41 ± 6.16 0.260
WHR 0.90 ± 0.08 0.89 ± 0.07 0.229
£: Independent t-test.
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but not significant yet.
c.56C>G polymorphism
The frequencies of allele G in the two groups of high and
low TG were respectively 0.055 and 0.045 that were not
significantly different from one another. Allele G frequency
in combined high and low TG groups was 0.05 with the
genotype distribution being within Hardy-Weinberg equi-
librium. We found a significant association between allele
G frequency and WHR but we failed to find any significant
association between serum TG (P = 0.594) and HDL-C
(P = 0.640) with c.56C>G polymorphism (Table 6).
Discussion
The results of our cross-sectional study show that
ApoA5 -1131T>C polymorphism is associated with TG
levels in a cohort of subjects from Babol-Iran. These
data add to those of studies performed on other human
populations [28-30]. Our finding that allele C carriers had
a higher chance (two folds) of having a high TG than
people with TT genotype is in agreement with haplotype
analyses conducted on Taiwanese population [31].
Allele C frequency of this polymorphism was 21% in
the high TG population (TG ≥150 mg/dl), 11% in the
low TG population (TG ≤103 mg/dl) and 16% in total
population. These values are close to allele C frequency
reported for other Caucasian populations, such as theTable 4 Mean ± SD for biochemical and anthropometric analy
significance for CC/TC versus TT genotype in men and wome
Parameter Women
Genotype P
CC & TC TT
TG (mg/dl) 178.04 ± 90.89 156.63 ± 95/09
Cholesterol (mg/dl) 193.43 ± 35.43 189.30 ± 39.86
HDL-C (mg/dl) 41.82 ± 13.59 43.19 ± 11.49
BMI (Kg/m2) 27.45 ± 3.68 27.63 ± 4.39
WHR 0.93 ± 0.06 0.92 ± 0.07
£: Independent t-test.Brazilians 16% [32] Hispanics 13-16% and Turks 13%
[23] but differ from other ethnic population like East
Asians 27-37% [29,33].
Subgroup analysis revealed a significant association be-
tween the rare allele frequency and high TG just in men
but not in women. These results are consistent with that
reported for a Chinese population [34].
Although other investigators have reported a signifi-
cant positive relationship between serum levels of total
cholesterol and LDL-C with -1131T>C genotype [35],
but our data failed to show such an association. The
present data indicate that subjects with the TT genotype
tended to show higher mean and minimum levels total
cholesterol in their sera as compared to those with CC
genotype. This trend was not statistically significant, but
regarding the role of total cholesterol and LDL-C levels
in the occurrence of CVD, it is worthy to examine if the
trend will achieve significance with a larger number of
volunteers.
Hypertriglyceridemia is a hallmark of MetS [2]. Regarding
the great impact of -1131T>C polymorphism on the TG
level, the association of this polymorphism with MetS has
been the subject of many population genetic studies. Thus,
the association of -1131T>C polymorphism with MetS has
been shown in Korean [36] and Chinese populations [37].
A meta-analysis also showed the significant association of
this polymorphism with MetS in Asian, but not in white
people [38].
Association of this allele with a spectrum of cardiac dis-
eases has been shown. Lima et al. reported this association
with atheromatosis in Coronary Artery Disease [39] and
Ding et al. with Acute Coronary Syndrome [40]. Besides, a
meta-analysis has indicated the association of this variant
with risk of Ischemic Stroke [41]. Also, the association of
-1131T>C polymorphism with CVD has been shown in
studies done on various populations, including Chinese
[42], Indian [43] and Korean [44].
With respect to the location of -1131T>C polymorph-
ism in the promoter of ApoA5 gene, its effect on gene
transcription and consequently serum ApoA5 levels




CC & TC TT
0.310 212.17 ± 196.36 150.24 ± 80.30 0.027
0.633 206.37 ± 46.48 203.77 ± 39.04 0.774
0.616 47.47 ± 14.44 51.19 ± 13.64 0.223
0.845 31.24 ± 7.41 29.37 ± 4.83 0.137
0.869 0.85 ± 0.06 0.89 ± 0.09 0.092
Table 6 Mean ± SD and P-value for biochemical and




TG (mg/dl) 178.05 ± 98.26 163.96 ± 113.40 0.594
Cholesterol (mg/dl) 199.95 ± 36.56 197.28 ± 39.45 0.773
LDL-C (mg/dl) 122.40 ± 28.15 118.26 ± 30.19 0.559
HDL-C (mg/dl) 45.10 ± 11.85 46.61 ± 13.57 0.633
BMI (Kg/m2) 28.60 ± 5.84 28.86 ± 5.14 0.838
WHR 0.85 ± 0.06 0.90 ± 0.08 0.040
£: Independent t-test.
Table 5 Odds ratio for the allele C carriers versus TT genotypes of -1131T>C (rs662799) polymorphism in occurrence of
high TG
Unadjusted model Adjusted with BMI
OR (CI 95%) P-value£ OR (CI 95%) P-value£
Allele C carriers versus TT genotype 1.97 (1.05–3.68) 0.034 2.03 (0.89–4.60) 0.090
£: logistic regression.
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[44]. Although, relationship between this variant with
ApoA5 level and TG has been reported in some studies
[26], this association was independent of ApoA5 levels
in some others [45]. Therefore, it has been hypothesized
that this association might be because of the strong rela-
tionship between -1131T>C polymorphism with disequi-
librium of polymorphisms of ApoC3 gene [46].
The frequency of the G Allele of ApoA5 c.56C>G
polymorphism in our population (5%) is close to the
corresponding values reported for Caucasians such as
Danish 6% [24], Turks 6% [47] and British 6% [48], as
well as populations like Brazilians 7% [32], but it is less
than that obtained for Costaricans 10.2% [49]. The rea-
son for similarities between results we obtained for our
Iranian population and those obtained for Caucasians
can be attributed to the close ethnic relationship be-
tween the two populations. Despite the low frequency
of the G allele of the c.56C>G polymorphism in our
population, we detected a significant association be-
tween this minor allele with WHR, a finding that
points to the strong influence of this polymorphism
on anthropometric parameters. The interaction of G
Allele of ApoA5 c.56C>G polymorphism with LPL
polymorphism to heighten the genetic susceptibility
to obesity have also been reported [50]. However, to
our knowledge, there is no data on the independent
effect of ApoA5 c.56C>G polymorphism on the an-
thropometric parameters in the literature.
WHR is shown to be a better predictor for MetS and
some other diseases [51-53]. Our present data indicate
that G allele of ApoA5 c.56C>G polymorphism had a
great impact on WHR. Therefore it is of interest to in-
vestigate other ethnic groups to confirm the influence of
this ApoA5 polymorphism on the WHR.
Results of a number of studies have shown an associ-
ation between the G allele of ApoA5 c.56C>G poly-
morphism and levels of TG, both in the general
population [45,54] and in subgroups of patients, like dia-
betics [55] and type III hyperlipidemias [56]. Although,
the mean TG level in our subjects who were heterozy-
gotes for allele G was higher than that of non-carriers
but possibly due to the small sample size, the difference
was not statistically significant. However, in consistent
with our data, a study on 1703 Costarican subjects didn’t
find any association between this variant and TG level
[49]. Likewise, data of another study on 1020 PuertoRican subjects, showed that c.56C>G polymorphism was
associated with levels of HDL-C but not TG in the sera
of their subjects [57]. These inconsistencies may be due
to ethnic differences or linkage disequilibrium with other
genetic factors.
Association of the minor allele of c.56C>G polymorph-
ism of ApoA5 with decreased HDL-C [25,49,57] and in-
creased LDL-C and total cholesterol [47] has been
reported. However, our data didn’t show this association,
maybe because of aforementioned reason.
In the end it is very important to consider the
strengths and weakness of the current study. One of the
highlights of our study is age and gender matched
groups, which significantly decrease the effects of these
factors on the outcomes of the study. On the other
hand, there are some limitation in this work including
low sample size, especially for c.56C>G polymorphism
that have lower frequency. Finally, we couldn’t evaluate
the association of all MetS indicators with these poly-
morphisms that would be the target of our future
studies.Conclusion
Our results indicate the association of two common
polymorphism of ApoA5 gene, -1131T>C and c.56C>G,
with respectively TG and WHR, both of which are indi-
cators of MetS. It could be concluded that modification
of dietary intake together with losing weight, increase
the physical activity and decrease environmental
stress are essential factors that might decrease MetS
frequency.
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